Sign in Subscribe
Big data

Real-World Insights into Metastatic Hormone-Sensitive Prostate Cancer Treatment Patterns

Strategic Insights

— 1 min read

Research published in European Urology Open Science has highlighted the importance of real-world evidence in guiding treatment decisions for metastatic hormone-sensitive prostate cancer (mHSPC). The study, conducted by an international team of researchers, analyzed health records and insurance claims from over 69,000 patients with mHSPC across eight European and North American databases. The findings revealed that age and comorbidity burden were the primary determinants of frontline therapy, with a clear shift towards the increased use of androgen receptor pathway inhibitors (ARPI)-based combinations from 2016 to 2020.

Key Takeaways:

  • The study analyzed health records and insurance claims from over 69,000 patients with metastatic hormone-sensitive prostate cancer (mHSPC) across eight European and North American databases.
  • The median age of patients ranged from 70 to 79 years, with the most prevalent comorbidities being arterial hypertension (71%), obesity (up to 46%), and diabetes mellitus (up to 32%).
  • Age and comorbidity burden emerged as the primary determinants of frontline therapy, with younger patients more frequently receiving androgen deprivation therapy (ADT) + chemotherapy or ADT + ARPI + chemotherapy.
  • The adoption of ARPI-based combinations rose steadily from 2016 to 2020, while the use of ADT + chemotherapy declined, and ADT monotherapy remained stable.
  • The study's findings highlight the importance of real-world evidence in guiding treatment decisions for mHSPC and promoting more inclusive, evidence-based care.

Statistics:

  • A total of 69,680 mHSPC patients were identified across eight databases, with 71% presenting with synchronous mHSPC.
  • The median age of patients ranged from 70 to 79 years.
  • 71% of patients had arterial hypertension, up to 46% had obesity, and up to 32% had diabetes mellitus as comorbidities.
  • The adoption of ARPI-based combinations rose from 36.6% in 2016 to 53.5% in 2020.
  • The use of ADT + chemotherapy declined from 28.1% in 2016 to 14.5% in 2020.

Sources:

  • European Urology Open Science. 2025;81:82-91.
  • NewsRx. Reports Outline Prostate Cancer Study Results from Cantonal Hospital (Real-world Evidence on Baseline Characteristics and Treatment in Metastatic Hormone-sensitive Prostate Cancer: Findings from the PIONEER 2.0 Big Data Investigation Group). Obesity & Diabetes Week. November 3, 2025; p 105.

Read more